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I would like to congratulate Shah and Smith for their excellent comprehensive review of 26 phenoconversion [1] . They used a narrow definition of personalized medicine restricted to 27 pharmacogenetics as they described phenoconversion as its Achilles hydroxyrisperidone ratio for CYP2D6 EMs, the ratio is <1 [6] . An inverted ratio, with higher 48 concentrations of risperidone than 9-hydroxyrisperidone, occurred in CYP2D6 PMs and was expected in 49 50% of CYP2D6 EMs taking paroxetine or fluoxetine [5] . Unfortunately, the RCT risperidone TDM data 50 was never published by the company in a peer-review journal but was only presented in a poster. In a 51 review article [7] , graphics summarized the TDM data from the RCT by focusing on the mean values of the 52 risperidone/9-hydroxyrisperidone ratio and the total concentration-to-dose ratio (C/D ratio), a measure of 53 risperidone clearance from the body. The total concentration is calculated by adding the risperidone and 9-54 hydroxyrisperidone plasma concentrations [7] . 55 In a naturalistic study of risperidone pharmacogenetics, 277 patients provided risperidone TDM 56 data [8]. Table 1 shows that an inverted ratio (risperidone/9-hydoxirisperidone ratio >1) was present in 
